Caris Life Sciences (CAI) closed at $23.96 on November 12, 2026, down 2.2% from the previous close, on volume of 3,285,020 shares (30-day average 3,904,369).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 15-Jan-2730 : 35 C | 2,800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Guggenheim Keeps Their Buy Rating on Caris Life Sciences, Inc. (CAI)
TipRanks (Tue, 10-Nov 7:45 AM ET)
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PRNewswire (Wed, 4-Nov 4:05 PM ET)
PRNewswire (Mon, 19-Oct 6:31 AM ET)
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
PRNewswire (Thu, 15-Oct 8:31 AM ET)
Market Chameleon (Wed, 14-Oct 7:51 AM ET)
PRNewswire (Wed, 14-Oct 8:31 AM ET)
PRNewswire (Tue, 8-Sep 6:30 AM ET)
PRNewswire (Wed, 2-Sep 8:31 AM ET)
PRNewswire (Thu, 27-Aug 8:31 AM ET)
Market Chameleon (Thu, 6-Aug 7:20 AM ET)
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.
As of November 12, 2026, CAI stock price declined to $23.96 with 3,285,020 million shares trading.
CAI has a beta of 2.48, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.16 to the broad based SPY ETF.
CAI has a market cap of $6.87 billion. This is considered a Mid Cap stock.
Last quarter Caris Life Sciences reported $275 million in Revenue and $.05 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that CAI belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
CAI has underperformed the market in the last year with a price return of -4.8% while the SPY ETF gained +12.0%. However, in the short term, CAI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +3.5% vs -1.5% return in SPY. But in the last 2 weeks, CAI shares have been beat by the market, returning -32.4% compared to an SPY return of -2.0%.
CAI support price is $23.36 and resistance is $25.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.
